{
    "Clinical Trial ID": "NCT00617942",
    "Intervention": [
        "干预一:",
        "合伙人1",
        "(未定义)",
        "干预2:",
        "共济会2",
        "(未定义)"
    ],
    "Eligibility": [
        "融入标准:",
        "乳房的 histologically 记录的腺癌",
        "ANC > 1000 个细胞",
        "女性;年龄 > 18 岁; Zubrod PS 0-1",
        "标签 > 100,000",
        "阶段IIA-IIIB 疾病",
        "总 bilirubin < 或 = ULN",
        "没有转移性疾病的证据 没有怀孕或哺乳",
        "没有此前系统治疗乳腺癌",
        "血清素 < 1.5 mg/dl 或 Creat Cl > 30 ml/min",
        "血清 ALT < 2.5 x ULN",
        "ER、PR 和 HER2 状态要求",
        "LVEF(MUGA/Echo)WNL的定义",
        "没有基线 > 2 神经病",
        "血液含量 > 9.0 gm/dl",
        "HER2+ 定义为 IHC 3+ 或 FISH 比 > 2.0"
    ],
    "Results": [
        "测量结果:",
        "完全病理反应率的患者数,在Q3周的卡博拉丁,每周Abraxane和每周Trastuzumab治疗后观察到在可复制和不可复制LABC中;",
        "这些数字代表RCB得分为0的患者,RCB代表残留癌症负担。",
        "时间框架:1年",
        "结果一:",
        "手臂/组名称: Cohort 1",
        "手臂/组 描述: [未指定]",
        "分析的参与者总数: 37",
        "尺寸类型: 数字",
        "测量单位:12名参与者",
        "结果二:",
        "手臂/组名称: Cohort 2",
        "手臂/组 描述: [未指定]",
        "分析的参与者总数: 23",
        "尺寸类型: 数字",
        "单位:参与者13人"
    ],
    "Adverse Events": [
        "意外事件一:",
        "总数: 7/37 (18.92%)",
        "gr 3port 感染, 1/37 (2.70%)",
        "流感病例 1/37 (2.70%)",
        "发烧性中毒性 1/37 (2.70%)",
        "gr 4 疮,受精体质 [1]1/37 (2.70%)",
        "腹泻 gr 2, 恶心 gr 3, 感染 gr 3 1/37 (2.70%)",
        "感染正常 ANC/病毒级别 1 1/37 (2.70%)",
        "脱水 3, 腹泻 3, 呕吐 3, HGB3, 恶心 3, K 3, 失眠 2 1/37 (2.70%)",
        "gr 3细胞炎 - 乳房 1/37 (2.70%)",
        "不利事件二:",
        "总数: 8/23 (34.78%)",
        "gr 3port 感染, 0/23 (0.00%)",
        "流感 0/23 (0.00%)",
        "发烧性中毒性 0/23 (0.00%)",
        "gr 4 疮,受精体质 [1]0/23 (0.00%)",
        "腹泻 gr 2, 恶心 gr 3, 感染 gr 3 0/23 (0.00%)",
        "感染正常 ANC/病毒等级 1 0/23 (0.00%)",
        "脱水 3, 腹泻 3, 呕吐 3, HGB3, 恶心 3, K 3, 失眠 2 0/23 (0.00%)",
        "gr 3细胞炎 - 乳房 0/23 (0.00%)"
    ]
}